Eisai's Partnership Initiatives

Change of licensing agreement for exclusive commercialization of the antiobesity agent lorcaserin hydrochloride (generic name, name in U.S. : BELVIQ/BELVIQ XR, hereafter BELVIQ) that was concluded in December 2016. Based on the change in the agreement, Eisai acquired all development and marketing rights for BELVIQ from Arena Pharmaceuticals.

License for marketing and co-promotion of the antiepileptic agent Zebinix (generic name: eslicarbazepine acetate) in Europe

Exclusive license agreement for worldwide research and development, manufacturing and sales of the anti-beta amyloid (Aβ) protofibril antibody BAN2401 for the treatment of Alzheimer's disease

• 1.
  Joint development/joint sales promotion related to the beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor E2609 and the antibeta-amyloid (A-beta) protofibril antibody BAN2401
• 2.
  Acquisition of option rights related to joint development/joint sales promotion of the anti-Alzheimer's agents anti-Aβ antibody aducanumab (BIIB037) and the anti-tau antibody under development by Biogen Inc.

Acquisition of the rights from the two companies for manufacturing active pharmaceutical ingredients (API) for Japan for the insomnia treatment/anaesthesia induction agent flunitrazepam (Eisai product name: Silece®, Chugai product name: Rohypnol®) as well as the marketing authorization held by Chugai for Rohypnol in Japan

License agreement for manufacturing and sales of the antiepileptic agent Zonegran (generic name: zonisamide) in Europe and Asia

Agreement for feasibility study for applying the JCR's blood-brain-barrier (BBB) penetration technology “J-Brain Cargo” to the discovery of new treatments

License agreement for the commercialization of safinamide (development code: ME2125) in Japan and Asia currently under clinical development in Japan for the treatment of Parkinson's disease

License agreement for worldwide development, manufacturing and sales of the antiepileptic agent Inovelon/Banzel (generic name: rufinamide)

• 1.
  Comprehensive marketing agreement concerning Parkinson's disease treatment Eldepryl (generic name: selegiline hydrochloride) in China
• 2.
  Marketing and distribution agreement concerning Parkinson's disease treatments Comtan® (generic name: entacapone) and Stalevo® (levodopa/entacapone/carbidopa three-compound combination agent) in China

Co-promotion of the pain treatment Lyrica (generic name: pregabalin) in Japan

Agreement for global co-development and co-promotion of the dual orexin receptor antagonist lemborexant (development code: E2006)

Comprehensive non-exclusive collaboration agreement for creating new diagnostics in the dementia area

Exclusive license for the development and marketing of the anti-insomnia agent Lunesta (generic name: eszopiclone) in Japan

Collaboration agreement for neurological drug discovery research

Implementation of new joint research for the discovery and development of new drugs targeting dementia

• 1.
  In the neurodegenerative disease field encompassing biomarker research, carry out joint research that includes 1) research concerning neuroinflammation, 2) research concerning neurovascular/mitochondria, and 3) research concerning proteostasis
• 2.
  Agreement to form major drug discovery alliance to develop new therapeutics for neurological diseases

Partnership in development and commercialization of the anticancer therapies targeting EZH2, including E7438 within Japan, as well as regarding the right of first negotiation for licensing rights in Asia

Collaboration agreement for evaluating Halaven in first-line HER2-negative advanced breast cancer in combination with Halozyme's investigational new drug PEGPH20, a PEGylated recombinant human hyaluronidase

License for the antiemetic agent Aloxi (generic name: palonosetron) in the U.S. and Canada (transferred following the acquisition of MGI Pharma, Inc. on January 28, 2008)

Acquisition of exclusive license to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore

Agreement for joint research on combination therapies of Merck & Co., Inc.'s (Kenilworth, NJ, USA) anti-PD-1 therapy, pembrolizumab, with Eisai's anticancer agents Lenvima (generic name: lenvatinib) and Halaven (generic name: eribulin)

Agreement with Novartis Pharmaceuticals Corporation (U.S.) on co-promotion of Lenvima in combination with everolimus in the U.S. for the treatment of patients with advanced renal cell carcinoma

Comprehensive marketing agreement concerning Orion's breast cancer drug Fareston (generic name: toremifene citrate) in China

Joint research and development concerning CBP/catenin inhibitor E7386 and others

• 1.
  Exclusive license on joint development and marketing of the anticancer agent Treakisym/Symbenda (generic name: bendamustine) in Japan
• 2.
  Exclusive development and marketing licenses in Singapore and South Korea

Development, sales and co-promotion of the fully human anti-TNF-α monoclonal antibody injectable agent Humira (generic name: adalimumab) in Japan, Taiwan and South Korea (EA Pharma and AbbVie undertake co-promotion for indications in the area of gastrointestinal disease (ulcerative colitis, Crohn's disease and intestinal Behcet's disease))

Agreement for integrating (absorption type split) Eisai's gastrointestinal disease treatment business with Ajinomoto Pharmaceuticals Co., Ltd. (Establishment of EA Pharma Co., Ltd.)

Exclusive rights for the development and marketing of liver disease/allergic disease agents Stronger Neo-Minophagen C (generic name: glycyrrhizic acid, combination preparation) and Glycyron Tablets (generic name: glycyrrhizic acid, combination tablets) in Euro-Asian countries where the products have not yet been sold, as well as exclusive first negotiation rights for exclusive marketing rights in China and other Euro-Asian countries where the products are already sold

Agreement for industry-academia joint research for the development of new drugs for inflammatory bowel disease that use biomarkers

Participation in a multi-stakeholder global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries

• 1.
  Joint research aimed at the development of new treatments for Chagas disease and malaria
• 2.
  Concluded a new joint-research agreement to develop a new antimalarial medicine based on antimalarial drug targets the joint research team identified in 2016

• 1.
  Collaboration and licensing agreement for new drug development for Chagas' disease and eumycetoma
• 2.
  Participation in the Drug Discovery Booster Consortium formed by DNDi with the aim of accelerating the discovery of new drugs for leishmaniasis and Chagas disease

Participation in public-private partnership aimed at bringing Japanese innovation to accelerate development of new medicines to cure infectious diseases in the developing world

• 1.
  Agreement for joint research for creating Wolbachia inhibitors (new antifilarial agents)
• 2.
  Agreement for joint research for developing antimalarial drugs

Participation in global partnership aimed at developing new drugs for filariasis (especially river blindness)

Agreement for joint research for the development of new antimalarial drugs

Identify research development collaboration projects targeting Eisai-developed compounds for the treatment of malaria and NTDs, and conduct joint research and development

Agreement for joint research aimed at developing new antimalarial agent

Agreement for joint research for development of new vaccines for Chagas' disease

Participation in global partnership aimed at creating innovative new drugs for tuberculosis

Agreement for providing free of charge DEC (diethylcarbamazine) tablets, a treatment for lymphatic filariasis, and participation in partnership for providing lymphatic filariasis diagnostic kits free of charge to endemic areas

Participation in consortium sponsored by WIPO for promoting the development of new drugs for tropical diseases